Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study.
E J Eichhorn, C M Heesch, J H Barnett...
https://pubmed.ncbi.nlm.nih.gov/7930255Completed
Phase 2
All Genders
ID00001402
Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2008-03-04
130
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation. Diseases of the heart like congestive heart failure (CHF), can cause the left ventricle to function improperly. Medications called beta-blockers appear to reverse the abnormalities in the left ventricle and frequently improve the function of the left ventricle in patients with different kinds of heart disease. How beta-blockers improve left ventricle function is unknown. One possible reason for improved function of the left ventricle with beta-blockers is improved blood flow to the heart muscle. When a region of the heart is active, it uses more fuel in the form of oxygen and sugar (glucose). As heart activity increases, blood flow to and from the area of activity increases also. Knowing these facts, researchers can use radioactive sugar (glucose) and positron emission tomography (PET) scans to observe what areas of the heart are receiving more blood flow. In this study researchers plan to measure glucose use in heart muscle and blood flow to the heart muscle in patients with CHF taking beta-blockers.
CONDITIONS
Official Title
PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%.
New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment.
Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel.
Dilated cardiomyopathy-if no coronary disease.
No pregnant or lactating women.
No women of child-bearing age not on proven birth control.
No severe hepatic or renal disease.
No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.
No primary valvular heart disease.
No PTCA or CABG within 3 months of enrollment.
No history of myocardial infarction or unstable angina within past 2 months.
No resting heart rate less than 60 bpm.
No A-V block greater than 1 degree block without pacemaker.
No severe ETOH abuse within 6 months of enrollment.
No severe bronchospasm.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart.
J K Kjekshus, O D Mjos
https://pubmed.ncbi.nlm.nih.gov/5032525